ZAP Surgical Raises $36M to Expand Brain Radiosurgery

A former retail space at Fukuoka Kieikai Hospital is due to become a brain radiosurgery suite. The planned glass-walled installation gives ZAP Surgical Systems a particularly visible example of its commercial argument: the design of a treatment machine can change which part of a hospital gets to offer the treatment.

The San Carlos, California company announced $36M in financing on October 19, 2026, led by Catalio Capital Management with continued support from Baheal, its strategic partner in China. The capital will support production and global deployment of ZAP-X, its dedicated cranial radiosurgery platform. For community hospitals and physician-led practices alongside academic centers, the proposition reaches into construction plans, source management and the decision to keep a patient's care local.

What ZAP Surgical's $36M financing supports

ZAP reports that it recently shipped its 50th ZAP-X system and that nearly 10,000 patients have been treated worldwide. The company is scaling production as it expands deployment across several kinds of healthcare institution. A shipment milestone gives the financing a tangible commercial backdrop, although it says little on its own about the economics of each installation.

John R. Adler, Jr., MD, ZAP's founder and CEO, established the company in 2014 after inventing CyberKnife and founding Accuray. His current company brings that history to a more narrowly focused machine, built for radiosurgery of the brain, head and neck. The operating question is how many providers can fit dedicated equipment into the care they already deliver.

Catalio Capital Management invests across healthcare and AI, including private, public and credit markets. Principal Nicholas von Guionneau joins ZAP as a board observer, bringing a background in clinical medicine and research on nerve regeneration and implantable neurodevices. The observer appointment connects a named investor representative to the company's continuing development, alongside Baheal's established role in China.

The new announcement does not specify a series label, valuation or financing instrument. ZAP separately announced a $78M Series E in November 2024, led by Qingdao Baheal Medical. That earlier round belongs in the company's history; adding selected announcements would not establish a verified lifetime funding total.

Why the treatment room belongs in the product discussion

The ZAP-X platform combines a linear accelerator with self-shielding and gyroscopic movement to deliver focused radiation from multiple directions. It is designed specifically for cranial stereotactic radiosurgery rather than general-purpose treatment across the body. ZAP describes a system capable of more than 1,000 non-coplanar beam angles, a technical feature that should be understood as delivery flexibility rather than a promise of superior outcomes for every patient.

For the provider, the design also changes the surrounding work. A linear accelerator generates the radiation beam without relying on radioactive cobalt sources that require management and eventual replacement. Built-in shielding can eliminate a dedicated radiation vault under typical usage, although shielding requirements vary by country. Those characteristics make the facility and the equipment part of the same purchasing conversation.

Dedicated cranial equipment still enters a market with existing treatment systems and established clinical practices. The FDA's ZAP-X clearance record identifies an earlier ZAP-X system as the predicate and CyberKnife M6 as a reference device. The record describes treatment planning, image-guided stereotactic radiosurgery and precision radiotherapy for indicated tumors, lesions and conditions in the brain, head and neck.

That regulatory language helps keep the commercial proposition precise. A hospital evaluating a machine has to consider its intended uses, the patients it serves and the resources needed around it. ZAP's installation argument addresses part of that work, giving facility planners something concrete to examine alongside the clinical team's assessment.

Regional expansion makes the access argument specific

Fukuoka Kieikai Hospital's planned program shows how the proposal changes at the customer level. The 260-bed community hospital currently refers its cranial radiosurgery patients to other facilities. ZAP's October 1 announcement describes a new program serving Fukuoka Prefecture and the wider Kyushu region, with installation expected to begin in October and first treatments anticipated in early 2027.

The hospital plans to place the equipment in a glass-walled, first-floor corner formerly occupied by a retail business. The location is more than an architectural flourish. It makes a specialized clinical capability visible within the ordinary footprint of a community institution, while the planned program would give some patients a local treatment option. Those are prospective benefits tied to a program that still has to open.

ZAP also announced an Australian installation with GenesisCare at St Vincent's Hospital in Sydney in September. That announcement anticipated installation in fall 2026 and first treatments before year-end. It extends the company's regional expansion narrative through a cancer-care provider, with a different institutional setting from Fukuoka's community hospital.

For a manufacturer using capital to expand production, these local details give global growth some practical definition. Each announced site has a room, a provider relationship and a clinical timetable attached to it. Shipping more systems creates a continuing need to turn those arrangements into functioning programs, supported by the people responsible for treating patients after the equipment arrives.

Psychiatric research adds a separate development path

ZAP is also exploring low-dose radiomodulation for neuropsychiatric conditions. The company describes preliminary first-in-human work in treatment-resistant depression and plans for broader multicenter trials beginning with depression and addiction. This research direction concerns the effect of precisely targeted radiation on brain activity, adding a scientific development path alongside the company's existing neuro-oncology business.

The distinction matters for anyone interpreting the financing. ZAP's own research and webinar materials identify neuromodulation as a use that is not a cleared indication for stereotactic radiosurgery. Preliminary research should therefore remain a research statement, with its own clinical questions, rather than becoming a claim that a commercially available tumor-treatment platform has established efficacy for psychiatric disease.

ZAP's current leadership team includes COO Derek T. DeScioli, CMO Hemmings Wu and CFO Nikita Kulkarni alongside John R. Adler, Jr. That combination of operating, medical and financial responsibilities fits the work described by the announcement: expanding the manufacture and deployment of a physical clinical system while new applications move through investigation.

The financing arrives with that work already taking recognizable forms. In Sydney, a cancer-care provider has announced plans to introduce a dedicated platform. In Fukuoka, a hospital that currently sends patients elsewhere is preparing a former shop for a different purpose. As ZAP builds more machines, its expansion will be experienced through those particular rooms, clinical teams and local referral decisions.